GlassScriptPhysician profile
Shivani Purohit
NPI 1689820763
$5,321.49
in general payments reported to CMS, 2019-2025
23 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $296 · 2021: $203 · 2022: $665 · 2023: $2,090 · 2024: $1,035 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,028 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,027.87 |
| Education | $336.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.31 | 2019-2025 | |
| Janssen Biotech, INC. | $848.22 | 2021-2024 | Tremfya, Simponi, Stelara |
| Amgen INC. | $622.74 | 2019-2024 | Tavneos, Enbrel, Otezla |
| Lilly USA, LLC | $515.77 | 2019-2024 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $453.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $333.51 | 2022-2024 | Saphnelo |
| Pfizer INC. | $246.63 | 2019-2024 | |
| Ucb, INC. | $158.59 | 2022-2023 | Cimzia |
| Aurinia Pharma U.S., INC. | $144.52 | 2022-2024 | Lupkynis |
| Genentech USA, INC. | $137.86 | 2019 | |
| Glaxosmithkline, LLC. | $133.56 | 2020-2024 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $102.10 | 2019 | |
| Fresenius Kabi USA, LLC | $99.98 | 2023 | Idacio |
| Mallinckrodt Hospital Products INC. | $76.55 | 2023-2024 | Acthar |
| Celgene Corporation | $67.10 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $57.90 | 2023-2024 | Renflexis, Hadlima |
| Curonix LLC | $39.52 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Endo Pharmaceuticals INC. | $37.72 | 2019 | |
| Avion Pharmaceuticals | $29.27 | 2020 | |
| Kyowa Kirin, INC. | $27.32 | 2024 | Crysvita |
| Hikma Pharmaceuticals USA | $15.03 | 2019 | |
| Depuy Synthes Sales INC. | $14.69 | 2020 | |
| Medexus Pharma, INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Purohit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.